ReviewJournal of psychopharmacology (Oxford, England)2024
Psychiatric risks for worsened mental health after psychedelic use.
Review in Journal of psychopharmacology (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Psychedelic-induced hypomania and mania: a systematic review and meta-analysis.Molecular psychiatry · 2026Pooled it
- Moving beyond 5-HTPsychopharmacology · 2026Article
- Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland.The international journal of neuropsychopharmacology · 2026Review
- Association Between Lifetime Hallucinogen Use and Valvular Heart Disease: Findings from the All of Us Research Program.Journal of psychoactive drugs · 2026Article
- Post-traumatic stress disorder symptoms following psychedelic use: a naturalistic survey study.Psychological medicine · 2026Article
- Stroboscopic light stimulation as a controllable probe of the psilocybin state: a mechanistic framework and a falsifiable prediction.Frontiers in pharmacology · 2026Article
- On the meaning of "plasticity" in neuroscience and mental health research and its relation to the action of psychedelic therapy.Frontiers in neuroscience · 2026Article
- Review
- Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community.Harm reduction journal · 2025Article
- Embracing change: impermanence acceptance mediates differences in death processing between long-term ayahuasca users and non-users.Psychopharmacology · 2025Article
- Leveraging family and caregiver support in psychedelic-assisted therapy: considerations for the treatment of adolescents.Child and adolescent psychiatry and mental health · 2025Review
- Exploring Psychedelics for Unmet Needs in Women's Reproductive Health.Psychedelic medicine (New Rochelle, N.Y.) · 2025Review
- Adverse Events Should Not Be Surprising in Psychedelic Research.Psychedelic medicine (New Rochelle, N.Y.) · 2025Article
- Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications.Brain sciences · 2025Review
- Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies.Frontiers in psychology · 2025Article
- Associations between psychedelic use and adverse outcomes in substance use disorders: a real-world EHR-based cohort study.Frontiers in psychiatry · 2025Article
- Psychedelic iatrogenic structural dissociation: an exploratory hypothesis on dissociative risks in psychedelic use.Frontiers in psychology · 2025Article
- Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach.Frontiers in psychiatry · 2025Article
- How to Mitigate Risk in the Treatment of Patients with Borderline Personality Disorder.Current psychiatry reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResurgent psychedelic research has largely supported the safety and efficacy of psychedelic therapy for the treatment of various psychiatric disorders. As psychedelic use and therapy increase in prevalence, so does the importance of understanding associated risks. Cases of prolonged negative psychological responses to psychedelic therapy seem to be rare; however, studies are limited by biases and small sample sizes. The current analytical approach was motivated by the question of whether rare but significant adverse effects have been under-sampled in psychedelic research studies.
methodsA "bottom margin analysis" approach was taken to focus on negative responders to psychedelic use in a pool of naturalistic, observational prospective studies (
resultsWe find that 16% of the cohort falls into the "negative responder" subset. Parsing the sample by self-reported history of psychiatric diagnoses, results revealed a disproportionate prevalence of negative responses among those reporting a prior personality disorder diagnosis (31%). One multivariate regression model indicated a greater than four-fold elevated risk of adverse psychological responses to psychedelics in the personality disorder subsample (
conclusionWe infer that the presence of a personality disorder may represent an elevated risk for psychedelic use and hypothesize that the importance of psychological support and good therapeutic alliance may be increased in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.